Drug Discovery@nature.com 31 January 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 31 January 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Biotechnology FREE POSTER  Antibody-drug conjugates for cancer therapy Made available with the generous support of  Millennium: The Takeda Oncology Company and Seattle Genetics    News Top 2013 FDA drug approvals doi:10.1038/nrd4239 Although the FDA's 27 new approvals are down from the 15-year high of 2012, the newcomers pack powerful commercial potential. Full Text Regulatory watch: Where do new medicines originate from in the EU? doi:10.1038/nrd4232 Hans-Georg Eichler and colleagues at the European Medicines Agency (EMA) analyse the nature of the originator companies of the 94 new active substances that received a positive opinion from the EMA licensing committee between 2010 and 2012. Full Text An audience with... Mads Krogsgaard Thomsen doi:10.1038/nrd4238 Mads Krogsgaard Thomsen celebrates his twentieth anniversary of overseeing R&D at Novo Nordisk. Full Text Court clears the way for Nexium alternative doi:10.1038/nrd4240 A US court has ruled that an alternative salt form of the gastroesophageal reflux drug Nexium does not infringe on patents that protect AstraZeneca's version, enabling Hanmi Pharmaceutical's competitor drug to remain on the US market. Full Text Analysis Top Regeneron revisits genomics doi:10.1038/scibx.2014.75 Regeneron has opened a genetics centre tasked with analysing the genomes of at least 100,000 patients in the next 5 years. Full Text Biosimilar competition: lessons from Europe doi:10.1038/nrd4210 Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars. Full Text Research Highlights Top Kidney disease: Targeting a faulty filter doi:10.1038/nrd4234 ML204, a small-molecule inhibitor of transient receptor potential channel 5, protects against injury in a mouse model of kidney damage. Full Text Phenotypic screening: A more rapid route to target deconvolution doi:10.1038/nrd4243 Combining activity-based protein profiling with phenotypic screening to improve drug target identification. Full Text Neurodevelopmental disorders: The gut–microbiome–brain connection doi:10.1038/nrd4235 Targeting the gut microbiota could be useful for treating behavioural symptoms in autism spectrum disorder. Full Text Research & Reviews Top PI3K and cancer: lessons, challenges and opportunities doi:10.1038/nrd4204 Fruman and Rommel discuss the complexity of the phosphoinositide 3-kinase signalling network in cancer, address challenges associated with therapeutic intervention and propose strategies to guide future research efforts. Full Text Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? doi:10.1038/nrd4189 The authors discuss how herpesvirus-encoded G protein-coupled receptors — which can hijack downstream signalling pathways in host cells — could be promising targets in certain inflammatory and proliferative diseases. Full Text The role of ligand efficiency metrics in drug discovery doi:10.1038/nrd4163 This article discusses how the application of ligand efficiency metrics (the molecular properties required to gain binding affinity for a drug target) has the potential to increase the quality of drug candidates. Full Text Inflammasomes in the CNS doi:10.1038/nrn3638 This Review describes our current understanding of the functions of different inflammasomes in the CNS and their roles in neurological diseases. Full Text Drug Discovery JOBS of the week Tier 2 Canada Research Chair in Molecular Pharmacology and Drug Discovery University of Ottawa Tenure track, Assistant / Associate Professor position with expertise in Drug Discovery: Michigan State University More Science jobs from Drug Discovery EVENT Advances in Cancer Drug Discovery 30.03.14 Cambridge, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.